Eurofins Scientific Shares Continue Their Ascent at Monday's Close on January 12
Eurofins Scientific closed the trading session on Monday, January 12 at 71.70 euros, marking an increase of 3.49% from the previous day's close of 69.28 euros. The stock continues its strong upward trajectory, significantly influenced by an upgrade in recommendation from Exane BNP Paribas on January 5, from underperform to outperform, with a revised price target of 75 euros.
Strong Weekly and Annual Performance
Eurofins Scientific closed the session on Monday, January 12 at 71.70 euros, up 3.49% from the previous day's 69.28 euros. The stock continues its strong upward trend from the previous week, notably driven by a significant upgrade in recommendation by Exane BNP Paribas on January 5, from underperform to outperform with a revised price target of 75 euros. Over seven days, the gain reached 15.65%, while the performance over three months is 15.79% and 46.12% over one year. Trading volumes remained moderate at 0.26% of the capital, indicating a technically healthy rise. The stock is now well above its medium-term moving averages, with the MM50 at 60.28 euros and the MM200 at 60.12 euros, confirming a strong bullish underlying trend. The RSI reached 93, an extreme overbought level indicating that the stock is technically overheated and could see a pause or consolidation in the short term, although the momentum remains strong.
Significant Technical Breakthrough in the Session
The session on January 12 marked a significant technical breakthrough: the price crossed the key resistance level of 69.28 euros, which was the previous day's high, and continued its ascent beyond the upper limit of the Bollinger Bands set at 70.46 euros. This channel breakout validates the continuation of the bullish movement initiated at the beginning of January. The MACD, in positive territory with a line at 2.68 above its signal of 1.85, confirms the strength of the buying momentum. Analysts from Exane BNP Paribas believe that the French testing and certification group is at a turning point that should finally enable it to generate growth and cash flow after many years of investment. Since the beginning of 2026, Eurofins has continued its share buyback program, with weekly details published in accordance with European regulations. Exane's price target of 75 euros suggests a remaining potential of 4.6%, while other analysts remain more cautious, with Morgan Stanley maintaining a target of 64 euros and Bernstein at 72.30 euros.
